China's healthcare system features a three-tier structure, with Class 3 Grade A (3A) public hospitals (1,848 total) as the top tier. These public hospitals are the most authoritative, concentrating 93-94% of the nation's leading experts and resources. Top resources are clustered in four major hubs: Beijing: excels in rare/complex diseases and advanced surgery. Shanghai: known for international environment, precision medicine, and advanced tech. Guangzhou: a southern leader in oncology, immunology, and cardiology. Shenzhen: an emerging hub for medical innovation driven by tech and biopharma. Choosing the right city, specific hospital, and expert team is crucial, as each center has unique specialty strengths.

Good‑quality Healthcare Resource Distribution in China

China’s healthcare system features a three-tier structure, with Class 3 Grade A (3A) public hospitals dominating top-tier care—93–94% of the 1,848 such facilities are public, housing leading experts and advanced resources. Quality is regionally concentrated: Beijing excels in rare/complex diseases and multidisciplinary surgery; Shanghai leads in precision medicine and internationalized services; Guangzhou offers strong oncology, cardiovascular, and immune-related expertise; Shenzhen emerges as an innovation hub via biotech and tech integration. Optimal outcomes require selecting the right city, hospital, and specialist team. Tailored navigation of these resources is essential for effective treatment planning.

In mid-July, a hospital in Guangzhou, China, successfully completed two implantations of a domestically developed ultra-flexible microelectrode brain-computer interface (BCI) system. More than one month after surgery, two patients with high-level spinal cord injuries have been able to move and click a computer cursor using only their thoughts. The implanted brain-computer interface system successfully captured and decoded neural signals, enabling patients to control external devices through brain activity. The implanted electrodes are only 3 micrometers thick, significantly reducing potential foreign-body reactions and scar tissue formation associated with traditional brain implants. Medical experts regard this achievement as a major breakthrough in brain-computer interface technology, offering new possibilities for restoring communication and functional independence in patients with severe motor impairments.

A 64-year-old female patient from Hong Kong with advanced Parkinson’s disease, presenting with refractory motor fluctuations and progressive limb rigidity despite optimized pharmacotherapy, underwent Deep Brain Stimulation (DBS) at Zhongshan People’s Hospital following unsuccessful treatment attempts elsewhere. Postoperatively, she exhibited significant symptomatic improvement, with notable recovery of motor function and substantial enhancement in quality of life. This case underscores the clinical utility of DBS as a precision intervention for mid-to-late stage Parkinson’s disease, and highlights the growing cross-regional medical collaboration between Guangdong and Hong Kong.

According to comprehensive reports from Chinese media, a hospital in Guangzhou, China, has successfully completed the clinical implantation of a new-generation domestically developed implantable fully magnetically levitated artificial heart. Comparable in size to an egg, this advanced life-support device was entirely independently designed, developed, and manufactured in China. With a pump diameter of only 34 millimeters, a thickness of 26 millimeters, and a total weight of approximately 90 grams, the device has achieved a global milestone by becoming the smallest and lightest commercially available artificial heart system in the world. Medical experts have described this breakthrough as a significant advancement in cardiovascular medicine, providing renewed hope for millions of patients suffering from advanced heart failure and requiring life-sustaining mechanical circulatory support. The total cost of the domestically developed artificial heart system has been reduced to below RMB 600,000, representing a nearly 40 percent decrease compared with previous solutions. All key components, core algorithms, and magnetic levitation control systems were independently developed in China, eliminating high overseas patent licensing costs and making this cutting-edge life-saving technology more accessible and affordable for ordinary patients.

A 72-year-old Chinese woman with a failed mitral bioprosthesis (implanted 7 years ago via sternotomy) and severe pulmonary hypertension was successfully treated by a team at West China Hospital (Chengdu, China). They performed the country's first combined transcatheter mitral valve-in-valve replacement (MVIV) via transfemoral–transseptal access with BATMAN technique—all on a beating heart, through a small groin incision, with only 10 mL blood loss. The patient was extubated immediately, walked the next day, and discharged in 7 days with excellent functional recovery. This breakthrough confirms the safety of this minimally invasive strategy and offers new hope for high-risk patients with valve failure—a first in China and rarely reported worldwide.

Mr. Xu, the first recipient of this BCI implant, lost hand grasping function due to a spinal cord injury from a car accident 10 years ago. Surgeons at Shanghai Huashan Hospital implanted electrode arrays in a procedure intended to allow him to perform grasping movements and regain daily living skills. The medical team reports that the device will be turned on and fine‑tuned after the surgical incision heals. Rehabilitation specialists will make home visits to guide standardized training, with gradual restoration of hand function expected through consistent practice. The NEO system, a domestically developed brain‑computer interface, decodes brain signals from the epidural space to identify the patient's movement intentions, and relays commands to external assistive devices that compensate for lost hand function. The device received regulatory approval in China on March 13, 2026.